Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€12.87

€12.87

-3.290%
-0.43
-3.290%
-
 
17.06.25 / Tradegate WKN: A1XDTV / Name: Uniqure / Stock / Biotechnology & Medical Research / Mid Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
JavaScript chart by amCharts 3.21.15
JavaScript chart by amCharts 3.21.15
JavaScript chart by amCharts 3.21.15JS chart by amCharts
Select a timeframe to show chart data
From: to:
Zoom:
Loading data...
Your prediction

Uniqure B.V. Stock

Uniqure B.V. took a tumble today and lost -€0.430 (-3.290%).
For the coming years our community has positive and negative things to say abot the Uniqure B.V. stock. Criterium "Worthwhile Investment for the next years" gathered the most positive votes but regarding "Innovation" there were negative voices in the community.

Pros and Cons of Uniqure B.V. in the next few years

Pros
?
M***** P*******
?
G***** c******* t* c**********
?
S********** s********
Cons
?
C******** o* t** e**********
?
W********* I********* f** t** n*** y****
?
B****
Tell us your opinion to access the 'Wisdom of the Crowds'

Performance of Uniqure B.V. vs. its peers

Security Change(%) 1w 1m 1y YTD 3y 5y
Uniqure B.V. -3.290% -10.063% 4.762% 193.836% -21.548% -4.348% -78.090%
Ironwood Pharmaceuticals -2.590% -16.547% 13.725% -89.057% -86.190% -94.604% -93.626%
Arrowhead Pharmaceuticals Inc. 0.630% -9.186% -4.257% -42.329% -27.034% -51.326% -57.281%
Novocure Ltd 1.680% -3.698% -1.463% -14.345% -46.789% -71.950% -72.311%

sharewise BeanCounterBot

The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.
Last updated at 2024-08-01

The financials of Uniqure, a player in the Biotechnology & Medical Research industry, depict a company grappling with significant challenges but also hints of potential growth. The data shows a precarious situation marked by escalating liabilities and negative earnings, but there are underlying indicators that may point to future improvements. This analysis dives deeper into the positives and negatives found within the financial statements, cash flows, income statements, and ratios.

Starting with an overview, Uniqure’s balance sheet presents a troubling picture. Total assets for 2023 amount to approximately $831.7 million, but the total liabilities stand at $624 million, resulting in a stockholder equity of just $207.7 million. Also alarming is the retained earnings, which sits at a staggering -$890.4 million, reflecting long-term operational losses. However, despite these troubling figures, the liquidity appears relatively healthy, with a net working capital of approximately $578 million, suggesting that Uniqure can meet its short-term obligations.

*Pros: *